Skip to main content

Psilocybin and Affective Function in Chronic Lower Back Pain Depression

This study seeks to provide insight on psilocybin's effects on mechanisms of chronic pain among patients with co-morbid chronic low back pain and depression (CLBP+D). Participants will receive either a single high-dose of psilocybin (25mg absolute dose) or methylphenidate (40mg absolute dose). Participants will be asked to complete assessments of pain, depressive symptoms, and more general questionnaires regarding the participants experiences during the experimental sessions and the associated enduring effects.

Status
recruiting
Phase
Phase 1
Institution
Johns Hopkins University
Principal investigator
David B Yaden, PhD
Start date
2024-04-22
End date
2026-12-30
Registry ID
NCT06355414

View trial record

Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.